AP NEWS
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

Hepatitis D - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019-2021: Product Description, Patent Details, Forecasted Sales & API Manufacturer Details by Country - ResearchAndMarkets.com

February 27, 2019

DUBLIN--(BUSINESS WIRE)--Feb 27, 2019--The “Hepatitis D - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report provides comprehensive insights about marketed and Phase III products for Hepatitis D. The report includes information of marketed products including their product description, patent details, forecasted sales till 2021 & API manufacturer details by country.

Global API Manufacturers of Marketed Products for Hepatitis D

Coverage of API manufacturers for Hepatitis D marketed products spanning across United States, Europe, China and India. The manufacturers’ details include manufacturers’ name along with their location.

Emerging Phase III Products for Hepatitis D

This report provides a comprehensive understanding of the emerging Phase III therapies for Hepatitis D which can turn out to be future prospective competitors for the marketed products. It will also put light on the current market trends. Their forecasted global sales are also provided till 2021.

Scope

  • A review of the marketed products for Hepatitis D including their description, route of synthesis, regulatory milestones, forecasted sales estimates till 2021 and API manufacturer details
  • Patent information coverage of the marketed products including the patent number, holder, grant and patent expiry details
  • API manufacturers for the marketed products with location details
  • Emerging Phase III product profiles for Hepatitis D including product description, developmental activities, licensors & collaborators and chemical information

Reasons to Buy

  • API intelligence for marketed drugs for the indication and gaining insights of API manufacturers
  • Evaluate the marketing status and patent details of products to exploit opportunities for generic drug development
  • Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to the indication
  • Establish a comprehensive understanding of the emerging Phase III products which can be future competitors in this space

Topics Covered

1. Report Introduction

2. Hepatitis D: Overview

  • Risk Factors
  • Causes
  • Symptoms
  • Pathophysiology
  • Prognosis
  • Diagnosis
  • Treatment

3. Comparative Analysis of Marketed and Emerging Products

4. Marketed Therapies

4.1. Drug 1: Company name

  • Product Description
  • Route of Synthesis
  • Mechanism of Action
  • Pharmacology
  • Pharmacodynamics
  • Pharmacokinetics
  • Adverse Reactions
  • Clinical Trials
  • Regulatory Milestones
  • Product Development Activities

4.1.1 Product Details

  • United States
  • Europe

4.1.2 Global Sales Assessment

  • Historical Global Sales
  • Forecasted Global Sales

4.1.3 Patent Details

5. Emerging Therapies (Phase III)

5.1 Drug Name: Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

5.1.1 Forecasted Global Sales

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/k95v4b/hepatitis_d?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190227005694/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Infectious Diseases Drugs,Liver and Kidney Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 02/27/2019 11:38 AM/DISC: 02/27/2019 11:38 AM

http://www.businesswire.com/news/home/20190227005694/en